Last reviewed · How we verify
GSK2982772 Immediate Release — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK2982772 Immediate Release (GSK2982772 Immediate Release) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK2982772 Immediate Release TARGET | GSK2982772 Immediate Release | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK2982772 Immediate Release CI watch — RSS
- GSK2982772 Immediate Release CI watch — Atom
- GSK2982772 Immediate Release CI watch — JSON
- GSK2982772 Immediate Release alone — RSS
Cite this brief
Drug Landscape (2026). GSK2982772 Immediate Release — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2982772-immediate-release. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing